ARCELLX Revenue, Growth & Competitor Profile

DBA ENCARTA THERAPEUTICS, INC.

Company Profile & Annual Report for Arcellx

Access the complete profile.

Arcellx Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	20271 Goldenrod Lane Suite 2099 Germantown, MD 20876

Note: Revenues for privately held companies are statistical evaluations.




Arcellx's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
• What industry is the company in?

Arcellx Annual Revenue and Growth Rate

Arcellx	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2020	Details in Premium Report
2019
2018
2017
2016

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Arcellx's revenues are gauged from an analysis of company filings.

Investor Activity

Arcellx has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
April 9, 2021	31	100%	$115 MM
Complete list of funding rounds and total amounts in the Company Report

Arcellx's Income Statement (based on Industry Averages)

	$ Millions (Industry Average)
Arcellx Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Arcellx is developing and marketing. Arcellx's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
SPARX PROTEIN Biological preparations for the treatment of cancer using polypeptides and genetically engineered cells; pharmaceutical preparations for targeting tissues based on select tissue markers and ligands; pharmaceutical preparations for the purpose of binding ligands using engineered polypeptides and receptors; pharmaceutical preparations for immunotherapy using polypeptides and genetically engineered cells; pharmaceutical preparations for immune cell therapy using polypeptides and genetically engineered cells	04/06/2020
SPARX PROTEINS Biological preparations for the treatment of cancer using polypeptides and genetically engineered cells; pharmaceutical preparations for targeting tissues based on select tissue markers and ligands; pharmaceutical preparations for the purpose of binding ligands using engineered polypeptides and receptors; pharmaceutical preparations for immunotherapy using polypeptides and genetically engineered cells; pharmaceutical preparations for immune cell therapy using polypeptides and genetically engineered cells	04/06/2020
ARC-T Biological preparations for the treatment of cancer using polypeptides and genetically engineered cells; pharmaceutical preparations for targeting tissues based on select tissue markers and ligands; pharmaceutical preparations for the purpose of binding ligands using engineered polypeptides and receptors; pharmaceutical preparations for immunotherapy using polypeptides and genetically engineered cells; pharmaceutical preparations for immune cell therapy using polypeptides and genetically engineered cells	05/07/2018

See all trademarks and details in the Full Report.

Recession Risk

Determine whether Arcellx grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof Arcellx is relative to the industry overall. While a new recession may strike a particular industry, measuring the industry and company's robustness during the last recession estimates its ability to weather future recessions.

Market Share of Arcellx's Largest Competitors

A competitive analysis shows these companies are in the same general field as Arcellx, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
ELANCO US	Greenfield, IN	100
LEIDOS	Reston, VA	71
OMNICARE	Cincinnati, OH	66
SCIENCE APPLICATIONS INTERNATIONAL	Reston, VA	51
INC RESEARCH	Morrisville, NC	41
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	38
COVANCE	Princeton, NJ	30
CEPHALON	Frazer, PA	29
FLUOR MARINE PROPULSION	West Mifflin, PA	21

Nearby Competitors

These companies are similar in business line and location to Arcellx. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
HENRY M. JACKSON FOUNDATION FOR ADVANCEMENT OF MILITARY MEDICINE	Bethesda, MD	100
OTSUKA AMERICA PHARMACEUTICAL	Rockville, MD	84
CYSTIC FIBROSIS FOUNDATION	Bethesda, MD	32
HUMAN GENOME SCIENCES	Rockville, MD	31
MESO SCALE DIAGNOSTICS	Rockville, MD	28
SUPERNUS PHARMACEUTICALSINC.	Rockville, MD	21

Future Competition: Arcellx's Fastest Growing Competitors

These companies are in the same general field as Arcellx and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)